1. 2023
  2. Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations

    the T2B! immunity against SARS-CoV-2 study group, 1 Feb 2023, In: Journal of autoimmunity. 135, 102984.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple Sclerosis

    the T2B! immunity against SARS-CoV-2 study group, Jan 2023, In: Annals of neurology. 93, 1, p. 103-108 6 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  4. 2022
  5. SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis

    T2B! immunity against SARS-CoV-2 study group, van Kempen, Z. L. E., Stalman, E. W., Steenhuis, M., Kummer, L. Y. L., van Dam, K. P. J., Wilbrink, M. F., Ten Brinke, A., van Ham, S. M., Kuijpers, T., Rispens, T., Eftimov, F., Wieske, L. & Killestein, J., 23 Dec 2022, (E-pub ahead of print) In: Journal of neurology, neurosurgery, and psychiatry.

    Research output: Contribution to journalArticleAcademicpeer-review

  6. Association between age and the host response in critically ill patients with sepsis

    Michels, E. H. A., Butler, J. M., Reijnders, T. D. Y., Cremer, O. L., Scicluna, B. P., Uhel, F., Peters-Sengers, H., Schultz, M. J., Knight, J. C., van Vught, L. A., van der Poll, T., MARS consortium, de Beer, F. M., Bos, L. D. J., Glas, G. J., Hoogendijk, A. J., van Hooijdonk, R. T. M., Horn, J., Huson, M. A., Schouten, L. R. A., & 12 othersStraat, M., Wieske, L., Wiewel, M. A., Witteveen, E., Bonten, M. J. M., Cremer, O. M., Ong, D. S. Y., Frencken, J. F., Klouwenberg, P. M. C. K., Koster‐Brouwer, M. E., van de Groep, K. & Verboom, D. M., 1 Dec 2022, In: Critical Care. 26, 1, 385.

    Research output: Contribution to journalArticleAcademicpeer-review

  7. Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases

    Wieske, L., Kummer, L. Y. L., van Dam, K. P. J., Stalman, E. W., van der Kooi, A. J., Raaphorst, J., Löwenberg, M., Takkenberg, R. B., Volkers, A. G., D'Haens, G. R. A. M., Tas, S. W., Spuls, P. I., Bekkenk, M. W., Musters, A. H., Post, N. F., Bosma, A. L., Hilhorst, M. L., Vegting, Y., Bemelman, F. J., Killestein, J., & 34 othersvan Kempen, Z. L. E., Voskuyl, A. E., Broens, B., Sanchez, A. P., Wolbink, G., Boekel, L., Rutgers, A., de Leeuw, K., Horváth, B., Verschuuren, J. J. G. M., Ruiter, A. M., van Ouwerkerk, L., van der Woude, D., Allaart, C. F., Teng, Y. K. O., van Paassen, P., Busch, M. H., Jallah, B. P., Brusse, E., van Doorn, P. A., Baars, A. E., Hijnen, D., Schreurs, C. R. G., van der Pol, W. L., Goedee, H. S., Steenhuis, M., Rispens, T., ten Brinke, A., Verstegen, N. J. M., Zwinderman, K. A. H., van Ham, S. M., T2B! immunity against SARS-CoV-2 study group, Kuijpers, T. W. & Eftimov, F., Dec 2022, In: BMC medicine. 20, 1, p. 100 100.

    Research output: Contribution to journalArticleAcademicpeer-review

  8. Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination

    the T2B! immunity against SARS-CoV-2 study group, 10 Nov 2022, In: Frontiers in neurology. 13, 1032830.

    Research output: Contribution to journalArticleAcademicpeer-review

  9. Comprehensive overview of autoantibody isotype and subclass distribution

    T2B Consortium, 1 Nov 2022, In: Journal of allergy and clinical immunology. 150, 5, p. 999-1010 12 p.

    Research output: Contribution to journalReview articleAcademicpeer-review

  10. SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period

    Boekel, L., Besten, Y. R., Hooijberg, F., Wartena, R., Steenhuis, M., Vogelzang, E., Leeuw, M., Atiqi, S., Tas, S. W., Lems, W. F., van Ham, S. M., Eftimov, F., Stalman, E. W., Wieske, L., Kuijpers, T. W., Voskuyl, A. E., van Vollenhoven, R. F., Gerritsen, M., Krieckaert, C., Rispens, T., & 3 othersBoers, M., Nurmohamed, M. T. & Wolbink, G., 1 Nov 2022, In: The Lancet Rheumatology. 4, 11, p. e747-e750

    Research output: Contribution to journalComment/Letter to the editorAcademic

  11. Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases

    Stalman, E. W., Wieske, L., van Dam, K. P. J., Kummer, L. Y., van Kempen, Z. L. E., Killestein, J., Volkers, A. G., Tas, S. W., Boekel, L., Wolbink, G. J., van der Kooi, A. J., Raaphorst, J., Löwenberg, M., Takkenberg, R. B., D'Haens, G. R. A. M., Spuls, P. I., Bekkenk, M. W., Musters, A. H., Post, N. F., Bosma, A. L., & 39 othersHilhorst, M. L., Vegting, Y., Bemelman, F. J., Voskuyl, A. E., Broens, B., Parra Sanchez, A., van Els, C. C. A. C. M., Wit, J. D., Rutgers, A., de Leeuw, K., Horváth, B., Verschuuren, J. J. G. M., Ruiter, A. M., van Ouwerkerk, L., van der Woude, D., Allaart, C. F., Teng, O. Y. K., van Paassen, P., Busch, M. H., Jallah, P. B. P., Brusse, E., van Doorn, P. A., Baars, A. E., Hijnen, D. J., Schreurs, C. R. G., van der Pol, W. L., Goedee, H. S., Steenhuis, M., Keijzer, S., Keijser, J. B. D., Boogaard, A., Cristianawati, O., ten Brinke, A., Verstegen, N. J. M., Zwinderman, K. A. H., Rispens, T., van Ham, S. M., Kuijpers, T. W. & Eftimov, F., 5 Sep 2022, In: Annals of the rheumatic diseases. 81, 12, p. 1757-1766 10 p., 222904.

    Research output: Contribution to journalArticleAcademicpeer-review

  12. Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod

    Target-to-B! (T2B!) SARS-CoV-2 study group, 1 Jul 2022, In: Neurology® neuroimmunology & neuroinflammation. 9, 4

    Research output: Contribution to journalArticleAcademicpeer-review

Previous 1 2 3 4 5 6 Next

ID: 5182908